Why did Amirang Clinic introduce AdipoLABs’ ‘REMISSION 1℃’ device?

Establishment of a specialized treatment room using about 20 devices... Raise body temperature to 42°C and combine hyperthermia and immunotherapy

The goal is to prevent cancer recurrence through effective cancer treatment, and CEO Kim Sun-man says, “We look forward to new hope for patients who cannot undergo surgery.”

[Medical Newspaper/Daily News = Reporter Oh In-gyu] High-frequency hyperthermia is a cancer treatment that raises body temperature by stably generating deep heat by generating heat on its own based on the fact that cancer cells are weak to heat.

It is being rapidly introduced into medical practice with the advantage that it helps activate the patient's metabolism and immunity when undergoing cancer treatment, and can help improve the effectiveness of the treatment when combined with radiation and chemotherapy.

Amirang Clinic, which is about to open its doors with the goal of providing the best treatment and support for patients suffering from cancer and their families, also chose high-frequency hyperthermia treatment. Recently, ‘REMISSION 1℃’ by AdipoLABs, a leading domestic company, has been introduced in 20 units at a time and is receiving great attention in the medical community with a large investment in building a specialized treatment room.

At the recently held opening ceremony, Kim Sun-man, Director doctor of Amirang Clinic said, “There are many theories on the occurrence of cancer, but the important thing is immunity,” and added, “We use high-frequency hyperthermia treatment and high-dose vitamin C treatment to improve immunity.” “By instilling this habit in patients, we want to become a space where we can treat cancer more effectively and prevent recurrence.”

REMISSION 1℃, a medical high-frequency hyperthermia, is a medical device manufactured and sold directly by AdipoLABs. It was approved by the Ministry of Food and Drug Safety for the purpose of cancer treatment in October 2015, and has obtained European CE certification, Halal certification, and Malaysian MDA certification. By transmitting high-frequency waves into the human body and the resulting frictional heat within the core, the body temperature can be safely raised to 42°C, allowing hyperthermia treatment and immunotherapy to be performed simultaneously.

It has a mechanism to generate deep heat through high-frequency to the human body and necrosis heat-sensitive cancer cells, so it is emerging as a new hope for cancer treatment not only in Korea but also in overseas cancer patients.

In particular, he said, “With this introduction based on confidence in our technology, we now have a high-frequency hyperthermia that is comparable to the leading university hospitals in Korea such as Seoul St. Mary’s Hospital and Gangnam Severance Hospital.” He added, “The same protocol, 1 hour and 30 minutes to 2 hours. “We are performing the treatment sufficiently over a period of time so that the anti-cancer effect can be maximized,” he explained.

In fact, REMISSION 1°C generates frictional heat through 0.46Mhz high-frequency waves in the cells through up-down, left-right vibration, rotation, and distortion of ions inside cells, killing cancer cells that are vulnerable to heat.

Specifically, when high-frequency electrical energy is applied, whenever the direction of the current changes, the molecules that make up the tissue vibrate and rub against each other, generating bioheat through rotational, twisting, and collision movements . Unlike other types of current, high-frequency current, which does not stimulate sensory or motor nerves, has the advantage of being able to heat specific parts of the body tissue without causing muscle contraction.

AdipoLABs, REMISSION 1℃ device picture

Director Kim cited the following as the advantages of high-frequency hyperthermia treatment: △ nature-friendly treatment △ no accumulation of toxicity △ repeated use △ possible combined treatment with other anti-cancer treatments △ increased immunity.

He also added that if it can be shown that the possibility of surgery is increased through heat and immunotherapy, it could give new hope to patients with inoperable pancreatic cancer, which usually leads to death at the time of diagnosis.

Meanwhile, Director Kim Sun-man is serving as vice chairman and a board member of IVRA, which is increasing its reputation as a collaborative organization for the treatment of COVID-19.

Expectations are also high for the REMISSION 1℃ Cancer Treatment Conference, which will discuss the latest findings with doctors from 25 countries around the world and over 200 domestic medical scholars at the 4th IVRA General Assembly, scheduled to be held at Maria Hall, Seoul St. Mary's Hospital on April 28. expressed.

At the end of the interview, Director Kim said, “We will achieve both differentiation in treatment and customized intensive treatment for patients through cancer treatment centered on high-frequency hyperthermia cancer treatment devices.” He repeatedly emphasized, “We will successfully accompany cancer patients by preventing recurrence and providing evidence-based, highest-level medical care by combining proven metabolic and nutritional treatments for each cancer type and improving patients’ lifestyle habits.”

링크: http://www.bosa.co.kr/news/articleView.html?idxno=2189062